The business of healthcare innovation in the Wharton School curriculum

The Business of Healthcare Innovation

Volumn , Issue , 2005, Pages 1-24

  Burns, Lawton R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84927951473     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511488672.002     Document Type: Chapter

References (39)

1. Lawton R. Burns, The Health Care Value Chain: Producers, Purchasers, and Providers (San Francisco: Jossey-Bass, 2002).
2. Peter Hussey, et al., “How Does the Quality of Care Compare in Five Countries?,” Health Affairs 23(3) (2004): 89-99.
3. Cinda Becker, “The Best Care Money can Buy?,” Modern Healthcare (August 9, 2004): 26-29.
4. “The Health of Nations: A Survey of Health-Care Finance,” Economist (July 17, 2004): 3-19.
5. David Cutler and Mark McClelland, “Is Technological Change in Medicine Worth it?,” Health Affairs 20(5) (2001): 11-29.
6. Value Group, The Value of Investment in Health Care: Better Care, Better Lives (http://www.aha.org/aha/value/index.html), accessed August 24, 2004.
7. Penny Mohr et al., The Impact of Medical Technology on Future Healthcare Costs (Bethesda, MD: Project Hope, 2001).
8. Rosemary Stevens, In Sickness and in Wealth (New York: Basic Books, 1989);
9. Paul Starr, The Social Transformation of American Medicine (New York: Basic Books, 1982).
10. Daniel Hecker, “HighTechnology Employment: A Broader View,” Monthly Labor Review (June 1999): 18-28.
11. Peter Lawyer et al., “High Science: A Best-Practice Formula for Driving Innovation,” In Vivo (April 2004): 70-82.
12. Michael Porter, Competitive Strategy (New York: Free Press, 1980).
13. Birger Wernerfeld, “A Resource Based View of the Firm,” Strategic Management Journal 5 (1984): 171-180;
14. Jay Barney, “Firm Resources and Sustained Competitive Advantage,” Journal of Management 17 (1991): 99-120.
15. Michael Porter, Competitive Advantage: Creating and Sustaining Superior Performance (New York: Free Press, 1985).
16. Jeffrey Dyer, Collaborative Advantage (Oxford: Oxford University Press, 2000);
17. Lawton R. Burns, The Health Care Value Chain (San Francisco, CA: Jossey-Bass, 2002).
18. Michael Beer and Nitin Nohria, Breaking the Code of Change (Boston: Harvard Business School Press, 2000);
19. Andrew Van de Ven, H. L. Angel, and M. S. Poole, (eds.), Research on the Management of Innovation (New York: Ballinger/Harper & Row, 1989);
20. Andrew Van de Ven, and M. S. Poole, “Explaining Development and Change in Organizations,” Academy of Management Review 20 (1995): 510-540;
21. Van de Ven et al., The Innovation Journey (Oxford: Oxford University Press, 1999).
22. Lawyer L. et al., “High Science.”
23. Stephen Williams and Paul Torrens, Introduction to Health Services, 5th edn (Albany, NY: Delmar Publishers, 1999);
24. Phoebe Barton, Understanding the US Health Services System (Chicago: Health Administration Press, 1999);
25. Anthony Kovner and Steven Jonas (eds.), Health Care Delivery in the United States, 7th edn (New York: Springer Publishing, 2002).
26. Federal Trade Commission and the Department of Justice, Improving Health Care: A Dose of Competition (July 2004), Available at http://www.ftc.gov.
27. Center for Medicare and Medicaid Services (CMS). Office of the Actuary.
28. Burns B., Health Care Value Chain.
29. David Ricker, personal communication.
30. Anna Wilde Mathews, “FDA Chief Targets Europe’s Controls on Drug Prices,” Wall Street Journal (September 25, 2003): A3, A8.
31. Ashish Singh, Chris Zook, and Norbert Hueltenschmidt, “Healthy Convergence,” In Vivo (July/August 2004): 61-68.
32. David Cassak, “Convergent Calling: An Interview with Medtronic’s Stephen Oesterle,” In Vivo (September 2003): 35-43.
33. Anita Raghavan, and Kathryn Kranhold, “GE May Offer $8.31 Billion for U.K.’s Amersham,” Wall Street Journal (October 10, 2003).
34. David Shiple et al., “Five Information Technologies Vitalize Life Sciences,” Forrester Research TechStrategy Brief (August 19, 2003).
35. Singh S. et al., “Healthy Convergence.”
36. Ross DeVol, America’s Biotech and Life Science Clusters (Milken Institute, 2004);
37. Kerry Dolan, “San DNAgo,” Forbes Magazine (May 26, 2003): 122-126.
38. Michael Porter, “Clusters and the New Economics of Competition,” Harvard Business Review (November-December 1998): 77-90.
39. Des Dearlove, “The Cluster Effect: Can Europe Clone Silicon Valley?,” Strategy + Business 24 (fall 2001): 67-75.